# Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

> **NCT07152678** · PHASE2 · RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Cancer
- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab (240 mg)
- **RADIATION:** Brachytherapy

## Key facts

- **NCT ID:** NCT07152678
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-09
- **Final completion:** 2028-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152678, "Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07152678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*